Risks of Anemia Drugs for Patients With Cancer to Get More Scrutiny

New York Times: "But in 1990 Dr. Anagnostou published some of the first evidence suggesting that Amgen’s then brand-new anemia drug, Epogen, might fuel the growth of tumors. Few people paid heed."